Abstract
We present a patient with 5 years systemic sclerosis with diffuse scin manifestations, capillaroscopic data to confirm diagnosis, elevated levels of ANA-antibodys, Anti-Sox-1, Anti-Ro-52 and Anti-Histoni in the course of lung adenocarcinoma (proven by fibrobronchoscopy and biopsy) and brain metastasis in consequence. From the clinical examination it is established diffuse scin manifestations, weakened vesicular respiration in right site of lung, astheno-adynamic syndrome, shortness of breath with usual physical exertion. From lung function testsр FVC is 58% anf FEV1 is 59%. The adenocarcinoma on a wide area in the right half of the lung and not indicated for surgical treatment. Patient was conducted 4 cours of chеmotherapy with Alimta + Cisplatin from marth 2016 г to jull 2016 year, 7 cours Docetaxel from februari 2017 year to septembre 2017 year, radiotherapy. One year later complaints appear from forget of words, hard reading and writing. Computed tomography (CT) shows intracranial tumor formation with heterogeneous structure in left frontal btain half – methastasis after lung adenocarcinoma. Was conducted operative removal of tumoral formation, postoperative radiotherapy and Depakin chrono 2 time for 500 мг daily. The treatment for systemic sclerosis was followed by 8 mg Methylprednisolon and 250 mg Cuprenil with good therapeutic effect.
References
1. Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol (2011) 40:78-83. doi: 10.1007/s12016-010-8198-y
2. Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. (2010) 69:1809-15. doi: 10.1136/ard.2009.114264
3. Shah AA, Casciola-Rosen L. Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol. (2015) 27:563-70. doi: 10.1097/BOR.0000000000000222
4. Shah AA, Rosen A, Hummers L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. (2010) 62:2787-95. doi: 10.1002/art.27549
5. Xu GJ, Shah AA, Li MZ et al. Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc Natl Acad Sci USA. (2016) 113:E7526-34. doi: 10.1073/pnas.1615990113
6. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer (1995) 76:910-4.
7. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis. (2003) 62:728-31. doi: 10.1136/ard.62.8.728
8. Kuo CF, Luo SF, Yu KH et al. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol. (2012) 41:44-9. doi: 10.3109/03009742.2011.618145
9. Colaci M, Giuggioli D, Sebastiani M et al. Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmun Rev. (2013) 12:374-
9. doi: 10.1016/j.autrev.2012.06.003
10. Okada K, Endo Y, Miyachi Y et al. Glycosaminoglycan and versican deposits in taxane-induced sclerosis. Br J Dermatol. (2015) 173:1054-8. doi: 10.1111/bjd.13899
11. Park B, Vemulapalli RC, Gupta A et al. Docetaxelinduced systemic sclerosis with internal organ involvement masquerading as congestive heart failure. Case Reports Immunol. (2017) 2017:4249157. doi: 10.1155/2017/4249157
12. Hung CH, Chan SH, Chu PM, Tsai KL. Docetaxel facilitates endothelial dysfunction through oxidative stress via modulation of protein kinase C Beta: the protective effects of sotrastaurin. Toxicol Sci. (2015) 145:59-67. doi: 10.1093/toxsci/kfv017
13. Fernandez-Madrid F, VandeVord PJ, Yang X et al. Antinuclear antibodies as potential markers of lung cancer. Clin Cancer Res. (1999) 5:1393-400.
14. Vlagea A, Falagan S, Gutierrez-Gutierrez G et al. Antinuclear antibodies and cancer: a literature review. Crit Rev Oncol Hematol.

This work is licensed under a Creative Commons Attribution 4.0 International License.
